Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Edaravone for Ischemia-Reperfusion Injury in Kidney Transplantation
NCT02644915Unknown
- Sponsor
- Xijing Hospital
- Start
- Mar 2016
- Primary completion
- Sep 2016
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial in ischemia-reperfusion injury (IRI) and delayed graft function (DGF) comparing Edaravone Group with Placebo Group (2 arms). Primary endpoints: Incidence of Delayed Graft Function at 1 week and Serum Creatinine at 1 week. Status: unknown.
02
Drugs
edaravone
03
Conditions
ischemia-reperfusion injury (IRI)delayed graft function (DGF)
Beyond the preview
Go deeper on NCT02644915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02644915.